Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols


EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.


Title Abstract Investigator
Biomarkers of Risk for Colorectal Neoplasia (Team Project #2) The goal of this project is to evaluate biomarkers in normal colonic mucosa to determine their relationship to the occurrence of short- and long-term ... Schoen, Robert E.
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers We hypothesize that our novel Biomarker Panel of Auto-antibodies can distinguish aggressive, symptom diagnosed lung cancer from non-aggressive, screen-detected ... Rom, William
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non-progressing Cancer Distinguishing aggressive cancers from non-aggressive or non-progressing cancers is an issue of both clinical and public health importance particularly for ... Li, Christopher
Body Fluids as a Source of Diagnostic Biomarkers Semmes, John
Body Fluids as a Source of Diagnostic Biomarkers: Breast Semmes, John
Body Fluids as a Source of Diagnostic Biomarkers: Prostate Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent ... Semmes, John
Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized treatment Breast-conserving lumpectomy followed by radiation therapy has been shown to be an alternative strategy, competitive to mastectomy, in preventing mortality ... Golubnitschaja, Prof. Dr. Olga
Breast Ductal Lavage Fluid Specimen Bank Trock, Bruce
Breast Reference Set Application: Anu Mathew-Meso Scale (2012) Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic ... Mathew, Anu
Breast Reference Set Application: Chris Li-FHCRC (2014) This application proposes to use Reference Set #1. We request access to serum samples collected at the time of breast biopsy from subjects with IC (n=30) or ... Li, Christopher
Breast Reference Set Application: Chris Li-FHCRC (2015) We propose to evaluate nine candidate biomarkers for ER+ breast cancer in samples from the EDRN Breast Cancer Reference Set. These biomarkers have been ... Li, Christopher
Breast Reference Set Application: GeorgeTuszynski-Temple (2012) As recommended by the review committee, we will analyze 30 invasive cancer cases and 30 benign controls from the EDRN breast reference set. Cases and controls ... Tuszynski, George
Breast Reference Set Application: Jendoubi-Milagen (2017) Jendoubi, Moncef
Breast Reference Set Application: Karen Abbott- University of Arkansas (2013) We are evaluating whether detection of a tumor-specific N-linked glycosylation known as B 1,6 branched N-glycan present on the glycoprotein periostin in breast ... Abbott, Karen
Breast Reference Set Application: Karen Anderson-ASU (2014) In order to increase the predictive value of tumor-specific antibodies for use as immunodiagnostics, our EDRN BDL has developed a novel protein microarray ... Anderson, Karen
Breast Reference Set Application: Pinku Mukherjee-CanDiag (2014) We would like to get all three sets of specimens, however, we are requesting Specimen Set 1 first: 30 subjects with invasive cancer and 30 subjects with benign ... Mukherjee, Pinku
Breast Reference Set Application: Richard Zangar-PNNL (2012) Our immediate goal is to define a set of biomarkers (composed of circulating plasma proteins) that can be used to distinguish between true and false screens, ... Zangar, Richard (Rick) C.
Breast tissue array Chia, David
CLUE Studies: Evaluating Biomarkers of Carcinogenesis Helzlsouer, Kathy
Canary TMA This protocol describes a multi-center, retrospective, case-cohort tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict ... Nelson, Peter S
Chemokine Prostate Cancer Biomarkers STUDY DESIGN 1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers ... Macoska, Jill
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential ... Liu, Alvin Y.
Clinical Validation of Molecular Signatures of Cervical Neoplasia Unger, Elizabeth R.
Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies Chan, Daniel
Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers Semmes, John
Colon Reference Set Application: Robert Getzenberg - Johns Hopkins (2008) The goal of this project is to confirm the early validation of CCSA-3 and CCSA-4 as biomarkers for the early detection of adenocarcinoma of the colon and ... Not listed
Colon Reference Set Application: Mary Disis - University of Washington (2008) The proposed study aims to validate the diagnostic value of a panel of serum antibodies for the early detection of colorectal cancer (CRC). We have developed a ... Disis, Mary L
Colon Reference Set Application: Moncef Jendoubi - Milagen (2006) Confidential Jendoubi, Moncef
Colon Reference Set Application: Nam Kim - DiaDexus (2008) The EDRN Colorectal reference samples will be useful in confirming the potential application of novel serum markers for colorectal cancer that can detect ... Kim, Nam
DCIS Team Project Both overtreatment and undertreatment of DCIS are pervasive problems given that no useful approaches for identifying which DCIS patients are likely or highly ... Li, Christopher
Announcement 6/2/2018
Thank you to everyone to made the 10th EDRN Scientific Workshop a success. The next event is the 33rd EDRN Steering Committee Meeting from September 5-6, 2018 in Boston, MA. Details will be available soon.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.